Mifepristone Outpatient Labour Induction — MOLI  

Labor, Induced Clinical Trial

Official title: Mifepristone Outpatient Labour Induction

Status Recruiting

Clinical Trial Summary

The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID-19 pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine. Proving the efficacy and safety of Mifepristone would significantly reduce pre-labour admission rates and hospital length of stay for pregnant women, who are at particularly higher risk of COVID-19, and reduce delivery costs.

Clinical Trial Description

The study is a double blinded, two arms, multi-centre randomised controlled clinical trial to investigate the clinical effectiveness, safety and resource utilisation of intervention for the induction of labour in low-risk women admitted to the hospital. Subjects will be randomised 1:1 to one of the two arms to receive:

Arm 1: Mifepristone + standard of care Arm 2: Placebo + standard of care

The study treatment will commence from the administration of the Mifepristone or placebo. The participants will be assessed 48 hours after treatment regimen will be completed as an in-patient. ;

Related Conditions & MeSH terms

• Labor, Induced

• NCT number: NCT05177510
• Study type: Interventional
• Source: Chelsea and Westminster NHS Foundation Trust
• Contact: Tess Cheetham
• Phone: 020 331 56825
• Email: tess.cheetham@nhs.net
• Status: Recruiting
• Phase: Phase 3
• Start date: August 25, 2023
• Completion date: October 9, 2026